Query String: cisplatin
BDBM92386 trans-DDP, 8 Cisplatin, 1
Cis-Platinum(II) trans-dichlorodiammineplatinum.(transplatin) camphorato platinum complex derivative cis-Platinum diamminedichloride Platinum(IV) Complex Pt(II) Complex cis-diamminedichloroplatinum(II)(cis-DDP) Cisplatin(cis-Diammenedichloroplatinum) dichloromethanediamine(platinum complex) cisplatin complex dichloroplatinumdiamine cisplatin US11952364, Example Control BDBM50028111 Platinum (II) complex
- Pflieger, M; Hamacher, A; Öz, T; Horstick-Muche, N; Boesen, B; Schrenk, C; Kassack, MU; Kurz, T Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance. Bioorg Med Chem 27: (2019)
- Zhang, L; Zheng, Y; Callahan, B; Belfort, M; Liu, Y Cisplatin inhibits protein splicing, suggesting inteins as therapeutic targets in mycobacteria. J Biol Chem 286: 1277-82 (2011)
- Wei, H; Gou, W; Gao, J; Ning, H; Song, Y; Li, D; Qin, Y; Hou, W; Li, Y Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. Eur J Med Chem 230: (2022)
- Stenzel, K; Hamacher, A; Hansen, FK; Gertzen, CGW; Senger, J; Marquardt, V; Marek, L; Marek, M; Romier, C; Remke, M; Jung, M; Gohlke, H; Kassack, MU; Kurz, T Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines. J Med Chem 60: 5334-5348 (2017)
- Asfaha, Y; Schrenk, C; Alves Avelar, LA; Lange, F; Wang, C; Bandolik, JJ; Hamacher, A; Kassack, MU; Kurz, T Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells. Bioorg Med Chem 28: (2020)
- Hazlitt, RA; Teitz, T; Bonga, JD; Fang, J; Diao, S; Iconaru, L; Yang, L; Goktug, AN; Currier, DG; Chen, T; Rankovic, Z; Min, J; Zuo, J Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss. J Med Chem 61: 7700-7709 (2018)
- Zang, YD; Wu, HJ; Chen, XY; Ma, ZL; Li, CJ; Ma, J; Chen, XG; Sheng, L; Zhang, S; Zhang, DM Synthesis and Biological Evaluation of Novel Psidium Meroterpenoid Derivatives against Cisplatin-Induced Acute Kidney Injury. J Med Chem 67: 14234-14255
- Horley, NJ; Beresford, KJ; Chawla, T; McCann, GJ; Ruparelia, KC; Gatchie, L; Sonawane, VR; Williams, IS; Tan, HL; Joshi, P; Bharate, SS; Kumar, V; Bharate, SB; Chaudhuri, B Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines. Eur J Med Chem 129: 159-174 (2017)
- Shin, SY; Jung, H; Ahn, S; Hwang, D; Yoon, H; Hyun, J; Yong, Y; Cho, HJ; Koh, D; Lee, YH; Lim, Y Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells. Bioorg Med Chem 22: 1809-20 (2014)
- Wang, CH; Wu, HT; Cheng, HM; Yen, TJ; Lu, IH; Chang, HC; Jao, SC; Shing, TK; Li, WS Inhibition of glutathione S-transferase M1 by new gabosine analogues is essential for overcoming cisplatin resistance in lung cancer cells. J Med Chem 54: 8574-81 (2011)
- Huo, Z; Liu, K; Zhang, X; Liang, Y; Sun, X Discovery of pyrimidine-bridged CA-4 CBSIs for the treatment of cervical cancer in combination with cisplatin with significantly reduced nephrotoxicity. Eur J Med Chem 235: (2022)
- Le, TV; Suh, JH; Kim, N; Park, HJ In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells. Bioorg Med Chem Lett 23: 2642-6 (2013)
- Huang, W; Liu, Y; Wang, J; Yuan, X; Jin, HW; Zhang, LR; Zhang, JT; Liu, ZM; Cui, JR Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. Eur J Med Chem 157: 887-897 (2018)
- Williams, IS; Joshi, P; Gatchie, L; Sharma, M; Satti, NK; Vishwakarma, RA; Chaudhuri, B; Bharate, SB Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Bioorg Med Chem Lett 27: 3683-3687 (2017)
- Cheng, JH; Huang, AM; Hour, TC; Yang, SC; Pu, YS; Lin, CN Antioxidant xanthone derivatives induce cell cycle arrest and apoptosis and enhance cell death induced by cisplatin in NTUB1 cells associated with ROS. Eur J Med Chem 46: 1222-31 (2011)
- Sharma, R; Gatchie, L; Williams, IS; Jain, SK; Vishwakarma, RA; Chaudhuri, B; Bharate, SB Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme. Bioorg Med Chem Lett 27: 5400-5403 (2017)
- Endo, S; Xia, S; Suyama, M; Morikawa, Y; Oguri, H; Hu, D; Ao, Y; Takahara, S; Horino, Y; Hayakawa, Y; Watanabe, Y; Gouda, H; Hara, A; Kuwata, K; Toyooka, N; Matsunaga, T; Ikari, A Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells. J Med Chem 60: 8441-8455 (2017)
- ChEMBL_2323985 Inhibition of ABCC1 (unknown origin) overexpressing human KBV cells mediated efflux assessed as cisplatin IC50 using cisplatin as substrate at 5 uM
- ChEMBL_2323986 Inhibition of ABCC1 (unknown origin) overexpressing human KBV cells mediated efflux assessed as cisplatin IC50 using cisplatin as substrate at 10 uM
- ChEMBL_2323987 Inhibition of ABCC1 (unknown origin) overexpressing human KBV cells mediated efflux assessed as cisplatin IC50 using cisplatin as substrate at 25 uM
- ChEMBL_2114436 (CHEMBL4823377) Inhibition of HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.7 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_2114440 (CHEMBL4823381) Inhibition of HDAC in human CAL-27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.7 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_1838326 (CHEMBL4338459) Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM)
- ChEMBL_1838330 (CHEMBL4338463) Inhibition of class 1 HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 63.2 uM)
- ChEMBL_1838431 (CHEMBL4338564) Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM)
- ChEMBL_1838432 (CHEMBL4338565) Inhibition of class 1 HDAC in human CAL27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 3.2 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 9.79 uM)
- ChEMBL_1838433 (CHEMBL4338566) Inhibition of class 1 HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.5 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 63.2 uM)
- ChEMBL_1838434 (CHEMBL4338567) Inhibition of class 1 HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 3.2 uM preincubated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 63.2 uM)
- ChEMBL_2114437 (CHEMBL4823378) Inhibition of HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 3 to 4 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_2114438 (CHEMBL4823379) Inhibition of HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 2 to 3 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_2114439 (CHEMBL4823380) Inhibition of HDAC in human Cal27CisR cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.3 to 0.5 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_2114441 (CHEMBL4823382) Inhibition of HDAC in human CAL-27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 3 to 4 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_2114442 (CHEMBL4823383) Inhibition of HDAC in human CAL-27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 2 to 3 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_2114443 (CHEMBL4823384) Inhibition of HDAC in human CAL-27 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 0.3 to 0.5 uM pretreated for 48 hrs followed by cisplatin addition and measured after 72 hrs by MTT assay (Rvb = 3.57 uM)
- ChEMBL_1747469 (CHEMBL4181979) Inhibition of recombinant human CYP1B1 expressed in HEK293 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 by MTT assay (Rvb = 65.01 +/- 7.01 uM)
- ChEMBL_1751562 (CHEMBL4186322) Inhibition of human CYP1B1 expressed in MDA-MB-468 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 6.6 uM (Rvb = 6.70+/- 0.7 uM)
- ChEMBL_1751563 (CHEMBL4186323) Inhibition of human CYP1B1 expressed in MDA-MB-468 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 20 uM (Rvb = 6.70+/- 0.7 uM)
- ChEMBL_1659850 (CHEMBL4009462) Inhibition of human CYP1B1 expressed in HEK293 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.02 uM by MTT assay (Rvb = 61 +/- 8 uM)
- ChEMBL_1659851 (CHEMBL4009463) Inhibition of human CYP1B1 expressed in HEK293 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.018 uM by MTT assay (Rvb = 61 +/- 8 uM)
- ChEMBL_1659852 (CHEMBL4009464) Inhibition of human CYP1B1 expressed in HEK293 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.016 uM by MTT assay (Rvb = 61 +/- 8 uM)
- ChEMBL_1659841 (CHEMBL4009453) Inhibition of human CYP1B1 expressed in human A2780 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.02 uM by MTT assay (Rvb = 40 +/- 4.9 uM)
- ChEMBL_1659842 (CHEMBL4009454) Inhibition of human CYP1B1 expressed in human A2780 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.018 uM by MTT assay (Rvb = 40 +/- 4.9 uM)
- ChEMBL_1659843 (CHEMBL4009455) Inhibition of human CYP1B1 expressed in human A2780 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 0.016 uM by MTT assay (Rvb = 40 +/- 4.9 uM)
- ChEMBL_2083515 (CHEMBL4739306) Reversal of MRP2-mediated multidrug resistance in human KBV cells assessed as cisplatin IC50 at 5 uM after 72 hrs in presence of cisplatin by MTT assay (Rvb = 4902.89 +/- 130.33 nM)
- ChEMBL_2083516 (CHEMBL4739307) Reversal of MRP2-mediated multidrug resistance in human KBV cells assessed as cisplatin IC50 at 10 uM after 72 hrs in presence of cisplatin by MTT assay (Rvb = 4902.89 +/- 130.33 nM)
- ChEMBL_1741911 (CHEMBL4157661) Inhibition of ABCB1 in human SW620/Ad300 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 0.61 +/- 0.03 microM)
- ChEMBL_1741912 (CHEMBL4157662) Inhibition of ABCB1 in human SW620/Ad300 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 20 uM after 72 hrs by MTT assay (Rvb = 0.61 +/- 0.03 microM)
- ChEMBL_1741913 (CHEMBL4157663) Inhibition of ABCB1 in human SW620/Ad300 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 4 uM after 72 hrs by MTT assay (Rvb = 0.61 +/- 0.03 microM)
- ChEMBL_1852720 (CHEMBL4353344) Inhibition of P-gp in HEK293/ABCB1 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 2 uM incubated for 48 hrs by MTT assay (Rvb = 8.08 uM)
- ChEMBL_1741947 (CHEMBL4157697) Inhibition of ABCB1 (unknown origin) expressed in HEK293T cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 7.22 +/- 0.45 microM)
- ChEMBL_1741948 (CHEMBL4157698) Inhibition of ABCB1 (unknown origin) expressed in HEK293T cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 20 uM after 72 hrs by MTT assay (Rvb = 7.22 +/- 0.45 microM)
- ChEMBL_1741949 (CHEMBL4157699) Inhibition of ABCB1 (unknown origin) expressed in HEK293T cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin IC50 at 4 uM after 72 hrs by MTT assay (Rvb = 7.22 +/- 0.45 microM)
- ChEMBL_1706498 (CHEMBL4057731) Inhibition of human CYP1B1 transfected in HEK293 cells assessed as cisplatin EC50 at 6 times IC50 by MTT assay (Rvb = 65 uM)
- ChEMBL_1670186 (CHEMBL4020074) Inhibition of full length human XPA expressed in Sf9 cells assessed as reduction in interaction of XPA with 32P-labeled cisplatin-modified dsDNA by EMSA
- Fluorescent Reporter Assay In vitro inhibition of the Mtu RecA Intein by Cisplatin-Splicing activity of the RecA intein was dertermined in the presence and absence of potential platinum (II) inhibitors using a fluorescent reporter assay.